UroGen Pharma (URGN) Net Margin (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Net Margin of 46.26% for Q1 2026, up 17021.0% year-on-year from N/an in Q1 2025, and down 294.49% on a QoQ basis from 23.79% in Q4 2025.
UroGen Pharma (URGN) Net Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Net Margin for 10 consecutive years, with 46.26% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 17021.0% year-over-year to 46.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 69.66% (up 4689.0% YoY) and the FY2025 annual result came in at 107.6%, down 194.0% from the prior year.
- Net Margin retreated to 46.26% in Q1 2026 per URGN's latest filing, from 23.79% in the prior quarter.
- Over the last five years, Net Margin for URGN reached as high as 23.79% in Q4 2025 and fell as low as 216.47% in Q1 2025.
- A 5-year average of 114.47% and a median of 121.34% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2025 — Net Margin sank 5335 bps — and 2026, when it surged 17021 bps.
- Year by year, Net Margin stood at 12.53% in 2022, then soared by 118 bps to 2.21% in 2023, then tumbled by 1235 bps to 25.04% in 2024, then soared by 195 bps to 23.79% in 2025, then sank by 294 bps to 46.26% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 46.26%, 23.79%, and 121.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -46.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.26% |
| Dec 31, 2025 | 23.79% |
| Sep 30, 2025 | -121.34% |
| Jun 30, 2025 | -206.24% |
| Mar 31, 2025 | -216.47% |
| Dec 31, 2024 | -25.04% |
| Sep 30, 2024 | -93.93% |
| Jun 30, 2024 | -152.89% |
| Mar 31, 2024 | -171.91% |
| Dec 31, 2023 | 2.21% |
| Sep 30, 2023 | -104.93% |
| Jun 30, 2023 | -114.18% |
| Mar 31, 2023 | -175.74% |
| Dec 31, 2022 | -12.53% |
| Sep 30, 2022 | -160.47% |
| Jun 30, 2022 | -160.75% |
| Mar 31, 2022 | -209.32% |
| Dec 31, 2021 | -11.43% |
| Sep 30, 2021 | -266.15% |
| Jun 30, 2021 | -201.21% |